Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corey A Carter

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Clinical Medicine Insights. Oncology|November 15, 2016
A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001Bryan Oronsky, Scott Caroen, Karen Zeman, et al.
Translational Oncology|April 17, 2016
Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical TrialMichelle M Kim, Hemant Parmar, Yue Cao, et al.
Case Reports in Oncology|May 18, 2017
RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological TumorChristina Brzezniak, Bryan Oronsky, Jane Trepel, et al.
The Lancet. Oncology|January 17, 2015
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trialAnish Thomas, Arun Rajan, Arlene Berman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2014
A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational studyAnish Thomas, Arun Rajan, Eva Szabo, et al.
The Lancet. Oncology|January 21, 2014
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trialArun Rajan, Corey A Carter, Arlene Berman, et al.
Cell Reports|March 7, 2019
APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic TumorsNitin Roper, Shaojian Gao, Tapan K Maity, et al.
Expert Opinion on Investigational Drugs|December 10, 2016
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trialsBryan Oronsky, Ramasamy Paulmurugan, Kira Foygel, et al.
The Lancet. Oncology|August 23, 2015
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 studyTony Reid, Bryan Oronsky, Jan Scicinski, et al.
Cold Spring Harbor Molecular Case Studies|December 1, 2016
Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment responseRomi Biswas, Shaojian Gao, Constance M Cultraro, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Clinical Medicine Insights. Oncology|November 15, 2016
A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001Bryan Oronsky, Scott Caroen, Karen Zeman, et al.
Translational Oncology|April 17, 2016
Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical TrialMichelle M Kim, Hemant Parmar, Yue Cao, et al.
Case Reports in Oncology|May 18, 2017
RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological TumorChristina Brzezniak, Bryan Oronsky, Jane Trepel, et al.
The Lancet. Oncology|January 17, 2015
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trialAnish Thomas, Arun Rajan, Arlene Berman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2014
A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational studyAnish Thomas, Arun Rajan, Eva Szabo, et al.
The Lancet. Oncology|January 21, 2014
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trialArun Rajan, Corey A Carter, Arlene Berman, et al.
Cell Reports|March 7, 2019
APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic TumorsNitin Roper, Shaojian Gao, Tapan K Maity, et al.
Expert Opinion on Investigational Drugs|December 10, 2016
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trialsBryan Oronsky, Ramasamy Paulmurugan, Kira Foygel, et al.
The Lancet. Oncology|August 23, 2015
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 studyTony Reid, Bryan Oronsky, Jan Scicinski, et al.
Cold Spring Harbor Molecular Case Studies|December 1, 2016
Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment responseRomi Biswas, Shaojian Gao, Constance M Cultraro, et al.
Pageof 6